Spectral Diagnostics Closes $5.6 Million Offering
02 Abril 2013 - 10:53AM
OTC Markets
Spectral Diagnostics Inc. (TSX: SDI) (OTC QX:
DIAGF) ("Spectral",
or the "Company") and Toray Industries, Inc.
("Toray") today
announced the completion of the previously announced $5.6
million private placement of the Company, comprised of a
total of
18,666,667 common shares in the capital of the Company
("Common Shares"),
at a price of $0.30 per Common Share
(the
"Private Placement").
Toray acquired 16,666,667 Common Shares in the
Private
Placement, at a price of $0.30 per
Common Share, for
$5 million. Following
completion of the Private
Placement, Toray's 16,666,667 Common Shares represent approximately
12.6% of the
issued and outstanding Common Shares, calculated on a non-diluted
basis
"We are very pleased to have Toray as a
shareholder and we
sincerely appreciate the support of existing investors who
participated in this
offering at a premium to market. This is indicative of the
confidence that they
have in our clinical development program and prospects for
Toraymyxin in the
U.S. market," said Anthony Businskas, Executive Vice President and
CFO of
Spectral.
"This strategic investment not only provides
additional funds
for the clinical trial, but also strengthens the existing
collaborative
relationship we have with Spectral. Toray will work with Spectral
to complete
the clinical study for U.S. FDA market approval of Toraymyxin and
together we
hope to accelerate the launch of this product into the U.S.
market," said
Kazuhiro Maruyama, Senior Vice President of Toray.
The net proceeds of the Private Placement will
be used to
continue to support the Company's Phase III EUPHRATES clinical
trial and
for general corporate purposes.
The acquisition of the Common Shares by Toray
was made for
investment purposes only, and not with the purpose of influencing
control or
direction over Spectral. Toray may acquire further Common
Shares, or dispose of
its holdings of Common Shares, as investment conditions
warrant.
About Spectral Diagnostics
Spectral is a Phase III company seeking U.S. FDA
approval for
its lead theranostics product (Toraymyxin) for the treatment of
septic shock.
Toraymyxin is a therapeutic hemoperfusion device that removes
endotoxin, which
can cause sepsis, from the bloodstream. Directed by the Company's
Endotoxin
Activity Assay (EAA™), the only FDA-cleared diagnostic for the risk
of
developing sepsis, Spectral's EUPHRATES trial is the world's first
theranostics
trial in the area of sepsis.
Spectral is listed on the Toronto Stock Exchange under the symbol SDI,
and on the
OTC QX under the symbol DIAGF. For more information please visit
www.spectraldx.com
About Toray Industries,
Inc.
Toray Industries, Inc. is a Japanese-based
manufacturer of
fibers, textiles, plastics, chemicals, IT related products, carbon
fiber
composite materials, environmental and engineering equipment, and
pharmaceutical
and medical products. In FY 2011, Toray was active in 23
countries and regions,
and had net sales of ¥1.6 trillion (approximately U.S.$19
billion). Toray manufactures the Toraymyxin hemoperfusion
device and has
licensed to Spectral the exclusive commercialisation rights to this
product in
the United States and granted the
Company
exclusive distribution rights in Canada.
Note: U.S. dollar amounts have been converted
from yen at the
exchange rate of ¥82.2 = U.S.$1, the
approximate
rate of exchange prevailing on March 31,
2012.
Forward-looking statement
Information in this news release that is not
current or
historical factual information may constitute forward looking
information within
the meaning of securities laws. Implicit in this information,
particularly in
respect of the future outlook of Spectral and anticipated events or
results, are
assumptions based on beliefs of Spectral's senior management as
well as
information currently available to it. While these assumptions were
considered
reasonable by Spectral at the time of preparation, they may prove
to be
incorrect.
Readers are cautioned that actual results
are subject to a
number of risks and uncertainties, including the availability of
funds and
resources to pursue R&D projects, the successful and timely
completion of
clinical studies, the ability of Spectral to take advantage of
business
opportunities in the biomedical industry, the granting of necessary
approvals by
regulatory authorities as well as general economic, market and
business
conditions, and could differ materially from what is currently
expected.
The TSX has not reviewed and does not accept
responsibility
for the adequacy or accuracy of this statement.
SOURCE: Spectral Diagnostics Inc.
For further information:
Spectral Diagnostics Inc.
Anthony Businskas
Executive Vice President and CFO
416-626-3233 ext.
2200
Adam Peeler
Investor Relations
416-815-0700 ext. 225
apeeler@tmxequicom.com
Spectral Medical (PK) (USOTC:EDTXF)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Spectral Medical (PK) (USOTC:EDTXF)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024